Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Receivables (2024 - 2025)

Gossamer Bio (GOSS) has 2 years of Receivables data on record, last reported at $9.6 million in Q3 2025.

  • For Q3 2025, Receivables rose 44.18% year-over-year to $9.6 million; the TTM value through Sep 2025 reached $9.6 million, up 44.18%, while the annual FY2024 figure was $5.5 million, N/A changed from the prior year.
  • Receivables reached $9.6 million in Q3 2025 per GOSS's latest filing, up from $8.0 million in the prior quarter.
  • Across five years, Receivables topped out at $9.6 million in Q3 2025 and bottomed at $3.9 million in Q2 2024.